Nationwide Fund Advisors held its position in Alkermes PLC (NASDAQ:ALKS) during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 5,000 shares of the company’s stock at the end of the 2nd quarter. Nationwide Fund Advisors’ holdings in Alkermes PLC were worth $290,000 at the end of the most recent quarter.
Several other institutional investors and hedge funds have also bought and sold shares of ALKS. Fiera Capital Corp acquired a new stake in shares of Alkermes PLC in the 2nd quarter worth about $37,717,000. First Trust Advisors LP raised its holdings in shares of Alkermes PLC by 37.6% in the 2nd quarter. First Trust Advisors LP now owns 979,813 shares of the company’s stock worth $56,800,000 after acquiring an additional 267,742 shares during the last quarter. Renaissance Technologies LLC acquired a new stake in shares of Alkermes PLC in the 1st quarter worth about $7,306,000. Los Angeles Capital Management & Equity Research Inc. acquired a new stake in shares of Alkermes PLC in the 2nd quarter worth about $4,958,000. Finally, Legal & General Group Plc raised its holdings in shares of Alkermes PLC by 10.2% in the 2nd quarter. Legal & General Group Plc now owns 654,744 shares of the company’s stock worth $37,956,000 after acquiring an additional 60,624 shares during the last quarter. Institutional investors own 98.19% of the company’s stock.
Alkermes PLC (NASDAQ ALKS) opened at $47.85 on Friday. Alkermes PLC has a 52-week low of $46.80 and a 52-week high of $63.40. The company has a debt-to-equity ratio of 0.23, a quick ratio of 2.72 and a current ratio of 3.05.
Alkermes PLC (NASDAQ:ALKS) last released its earnings results on Thursday, October 26th. The company reported $0.03 earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.01) by $0.04. Alkermes PLC had a negative net margin of 20.12% and a negative return on equity of 7.27%. The firm had revenue of $217.40 million during the quarter, compared to the consensus estimate of $231.29 million. During the same period in the prior year, the firm earned ($0.09) EPS. The company’s revenue was up 20.6% compared to the same quarter last year. equities research analysts forecast that Alkermes PLC will post -0.59 earnings per share for the current fiscal year.
ILLEGAL ACTIVITY WARNING: “Alkermes PLC (ALKS) Position Maintained by Nationwide Fund Advisors” was first reported by Sports Perspectives and is the sole property of of Sports Perspectives. If you are reading this article on another site, it was illegally copied and reposted in violation of U.S. and international copyright and trademark legislation. The correct version of this article can be viewed at https://sportsperspectives.com/2017/11/11/alkermes-plc-alks-position-maintained-by-nationwide-fund-advisors.html.
A number of equities research analysts have issued reports on ALKS shares. ValuEngine downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Thursday, July 27th. BidaskClub downgraded shares of Alkermes PLC from a “hold” rating to a “sell” rating in a research report on Monday, July 31st. Zacks Investment Research raised shares of Alkermes PLC from a “sell” rating to a “hold” rating in a research report on Wednesday, August 2nd. Jefferies Group LLC set a $69.00 price objective on shares of Alkermes PLC and gave the stock a “buy” rating in a research report on Friday, August 25th. Finally, Barclays PLC downgraded shares of Alkermes PLC from an “overweight” rating to an “equal weight” rating and reduced their price objective for the stock from $66.00 to $50.00 in a research report on Monday, October 16th. Two equities research analysts have rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the stock. The stock has a consensus rating of “Hold” and a consensus price target of $63.55.
In related news, Director Richard F. Pops sold 50,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $48.87, for a total value of $2,443,500.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CAO Kathryn L. Biberstein sold 13,566 shares of the firm’s stock in a transaction that occurred on Monday, September 11th. The stock was sold at an average price of $51.29, for a total transaction of $695,800.14. Following the completion of the transaction, the chief accounting officer now directly owns 70,455 shares of the company’s stock, valued at $3,613,636.95. The disclosure for this sale can be found here. Insiders have sold a total of 102,498 shares of company stock valued at $5,018,010 over the last three months. Insiders own 5.34% of the company’s stock.
Alkermes PLC Company Profile
Alkermes plc is a biopharmaceutical company. The Company is engaged in the researching, developing and commercializing pharmaceutical products that are designed to address medical needs of patients in therapeutic areas. The Company has a portfolio of marketed drug products and a clinical pipeline of products that address central nervous system (CNS) disorders, such as schizophrenia, depression, addiction and multiple sclerosis (MS).
Receive News & Ratings for Alkermes PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alkermes PLC and related companies with MarketBeat.com's FREE daily email newsletter.